Case report of extensive metabolism by aldehyde oxidase in humans: Pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans

References

• Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308–316.
   PubMed Web of Science ®Google Scholar
• Beedham C. (1987). Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24:85–127.
   PubMedGoogle Scholar
• Beedham C, Miceli JJ, Obach RS. (2003). Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 23:229–232.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, Loi CM. (2010). In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by aldehyde oxidase. Drug Metab Dispos 38:641–654.
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA. (2007). Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766–1780.
   PubMed Web of Science ®Google Scholar
• Diamond S, Boer J, Maduskuie TP Jr, Falahatpisheh N, Li Y, Yeleswaram S. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–1285.
   PubMed Web of Science ®Google Scholar
• Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, Watanabe T. (1999). Aldehyde oxidase-dependant marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 27:83–98.
   Google Scholar
• Itoh K, Maruyama H, Adachi M, Hoshino K, Watanabe N, Tanaka Y. (2007). Lack of formation of aldehyde oxidase dimer possibly due to 377G>A nucleotide substitution. Drug Metab Dispos 35:1860–1864.
   PubMedGoogle Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. (1996). Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273–310.
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. (1996). Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm Drug Dispos 17:273–310.
   PubMed Web of Science ®Google Scholar
• Johns DG. (1967). Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 46:1492–1505.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K, Ohta S. (2006). Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83–98.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Sugihara K, Nakatani K, Ohta S, Ohhara T, Ninomiya S, Green CE, Tyson CA. (1999). Variation of hepatic methotrexate 7-hydroxylase activity in animals and humans. IUBMB Life 48:607–611.
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715.
   PubMed Web of Science ®Google Scholar
• Massey V, Komai H, Palmer G, Elion GB. (1970). On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem 245:2837–2844.
   PubMed Web of Science ®Google Scholar
• Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H, Aoki S, Akahane A, Iwashita A, Matsuoka N. (2007). Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson’s disease and cognition. J Pharmacol Exp Ther 323:708–719.
   PubMed Web of Science ®Google Scholar
• Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, Matsuya T, Miyoshi S, Nishimura S, Matsuoka N. (2008a). Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. J Nucl Med 49:1183–1188.
   PubMedGoogle Scholar
• Mugford CA, Mortillo M, Mico BA, Tarloff JB. (1992). 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Fundam Appl Toxicol 19:43–49.
   PubMedGoogle Scholar
• Mugford CA, Mortillo M, Mico BA, Tarloff JB. (1992). 1-Aminobenzotriazole-induced destruction of hepatic and renal cytochromes P450 in male Sprague-Dawley rats. Fundam Appl Toxicol 19:43–49.
   PubMedGoogle Scholar
• Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. (2001). Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29:1316–1324.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Mathews JM. (1981). Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyneprotoporphyrin IX adduct. Biochem J 195:761–764.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Masubuchi A, Yamamura M, Watanabe N, Hiratsuka M, Mizugaki M, Itoh K, Tanaka Y. (2006). Rat strain differences in stereospecific 2-oxidation of RS-8359, a reversible and selective MAO-A inhibitor, by aldehyde oxidase. Biopharm Drug Dispos 27:247–255.
   PubMed Web of Science ®Google Scholar
• Sugihara K, Kitamura S, Tatsumi K. (1995). Strain differences of liver aldehyde oxidase activity in rats. Biochem Mol Biol Int 37:861–869.
   PubMedGoogle Scholar
• Wishart DS. (2007). Improving early drug discovery through ADME modelling: an overview. Drugs R D 8:349–362.
   PubMedGoogle Scholar
• Zientek M, Jiang Y, Youdim K, Obach RS. (2010). In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. Drug Metab Dispos 38:1322–1327.
   PubMed Web of Science ®Google Scholar